When you consider the fact that I'm supposed to get one of those roter rooter jobs up the bad place at some point- 80% sounds just fine with me- I'll take my chances with the other 20%. This whole area is best handled through the mail. ~ stoney
EXAS: Exact Sciences
- Thread starter Landis82
- Start date
Is this a potential problem? The price dropped over $0.50 just after the news.
7:16 p.m. 10/16/2007
DOW JONES NEWSWIRES
Exact Sciences Corp. (EXAS) received a warning letter from the Food and Drug Administration's Office of In Vitro Diagnostic Device Evaluation and Safety on regulatory matters related to its DNA technology for colorectal cancer screening.
The FDA believes that the PreGen-Plus assay requires premarket approval or clearance, according to Exact Sciences, a Maynard, Mass., applied genomics company.
Exact said it is working with the FDA to pursue the appropriate filing strategy for the product and will meet with the agency within the coming weeks.
7:16 p.m. 10/16/2007
DOW JONES NEWSWIRES
Exact Sciences Corp. (EXAS) received a warning letter from the Food and Drug Administration's Office of In Vitro Diagnostic Device Evaluation and Safety on regulatory matters related to its DNA technology for colorectal cancer screening.
The FDA believes that the PreGen-Plus assay requires premarket approval or clearance, according to Exact Sciences, a Maynard, Mass., applied genomics company.
Exact said it is working with the FDA to pursue the appropriate filing strategy for the product and will meet with the agency within the coming weeks.
2 year base. Hmmm, 4-bagger. $5 is the threshold for some institutional "acceptibility" but.........institutions already own half the float. I'll skip ROE. Ditto for moving paper vs good story.
We'll see IF that speed is sustainable.
Give MY regards to Longhorns...........do the Dew.
We'll see IF that speed is sustainable.
Give MY regards to Longhorns...........do the Dew.
And there goes my profit out the buttocks
...EXAS -$1.67 or 28% in pre market.EXACT Sciences announced that it has received a Warning Letter from the Food and Drug Administration's (FDA) Office of In Vitro Diagnostic Device Evaluation and Safety regarding regulatory matters related to its DNA technology for colorectal cancer screening.
Great.
...EXAS -$1.67 or 28% in pre market.EXACT Sciences announced that it has received a Warning Letter from the Food and Drug Administration's (FDA) Office of In Vitro Diagnostic Device Evaluation and Safety regarding regulatory matters related to its DNA technology for colorectal cancer screening.
Great.
Do you think this letter is just a small hurdle / technicality which EXAS can remedy?
A buy op if so?
WOW. the fda sure has some shitty timing.